CRISPR Therapeutics– tag –
-
CRISPR Therapeutics Anticipates CASGEVY Market Expansion and Key Pipeline Catalysts by Year-End 2026
MarketBeat USA Overview CRISPR Therapeutics expresses strong optimism for the continued market adoption of its approved gene-editing therapy, CASGEVY, and anticipates significant data updates from multiple key pipeline programs by the en... -
CRISPR Therapeutics Forges Long-Term Growth with In Vivo Editing and Gene Insertion Following CASGEVY Approval
The Motley Fool USA Overview CRISPR Therapeutics reportedly aims for significant growth over the next decade by building on the commercialization of its approved sickle cell disease and transfusion-dependent beta-thalassemia therapy, CAS... -
CRISPR Therapeutics to Detail Pipeline Progress at Morgan Stanley Global Healthcare Conference
CRISPR Therapeutics Press Releases USA Overview CRISPR Therapeutics announced its management will participate in the Morgan Stanley 24th Global Healthcare Conference on September 10, 2026. This engagement provides a critical platform for... -
CRISPR Therapeutics Reports Deep, Durable Lipid Lowering from In Vivo Gene Editor CTX310 in Phase 1a Trial
MarketScreener (CRISPR Therapeutics) Switzerland Overview CRISPR Therapeutics AG announced compelling one-year durability data from its Phase 1a clinical trial of CTX310, an in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A s... -
CRISPR-Cas9 Breakthrough: CTX310 Delivers Sustained Lipid Control for Dyslipidemia in Phase 1a Trial, Published in NEJM
The New England Journal of Medicine USA Overview CRISPR Therapeutics' CTX310, a novel CRISPR-Cas9 gene-editing therapy, has demonstrated sustained and profound reductions in key lipid markers—angiopoietin-like 3 (ANGPTL3), triglycerides,... -
CRISPR Therapeutics Diversifies Pipeline into In Vivo Gene Editing and Off-the-Shelf CAR-T Cell Therapies, Leveraging Casgevy Commercialization Experience
Venture Atlas USA Overview CRISPR Therapeutics is strategically diversifying its pipeline, leveraging its commercialization experience with Casgevy, into in vivo gene editing programs (CTX310, CTX320, CTX340, CTX460) and allogeneic off-t... -
Gene Editing Startup Race Intensifies: CRISPR Therapeutics Leads in Commercialization, Intellia Advances In Vivo Phase 3, Beam Demonstrates Base Editing Versatility Across Human Therapies
New Market Pitch USA Overview A New Market Pitch analysis reveals CRISPR Therapeutics leads in commercialization with approved therapies, while Intellia Therapeutics shows significant progress in Phase 3 in vivo gene editing trials. Beam... -
Gene and Cell Therapy See Multiple Breakthroughs: Orca Bio’s TREGZI Receives FDA Approval, Vertex/CRISPR’s CASGEVY Expands Pediatric Indication, and Carsgen’s Satri-cel Gains China Approval
YouTube (LucidQuest) USA, China Overview According to a July 9, 2026, gene and cell therapy update, Orca Bio's precision engineered cell therapy, TREGZI, received FDA approval, offering a new option for matched donor allogeneic transplan... -
U.S. FDA RMAT Designations Surge to 165 Total, with Rocket Pharmaceuticals (5) and CRISPR Therapeutics (4) Leading the Way
BioInformant USA Overview As of July 15, 2026, the cumulative number of Regenerative Medicine Advanced Therapy (RMAT) designations publicly announced by the U.S. FDA has reached 165. Rocket Pharmaceuticals and CRISPR Therapeutics are not... -
FDA Approves Casgevy for Expanded Use in Pediatric Patients Aged 2 and Older with Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Seeking Alpha USA Overview Crispr Therapeutics and Vertex Pharmaceuticals announced that the U.S. FDA has approved an expanded indication for Casgevy (exagamglogene autotemcel) to include pediatric patients aged 2 and older with sickle c...
12